In this issue:
- Integrating quality of life and survival in systemic therapy for advanced HCC
- What is a safe washout period for ICIs prior to liver transplantation?
- Value of non-invasive test dynamics in guiding HCC surveillance decisions
- Adjuvant TACE for HCC after curative resection
- Global burden of HBV-related liver disease
- Adjuvant ICIs in HCC patients at high risk for recurrence after resection
- Second-line regorafenib in patients with unresectable HCC
- Second-line antidiabetic drugs: Friend or foe of the liver?
- Radiation-induced liver injury
Please login below to download this issue (PDF)